论文部分内容阅读
房颤(atrial fibrillation)是一种最常见的心律失常疾病,并且随着人群老龄化的趋势,其患病率和发病率也逐年增高[1]。房颤可增加中风、血栓栓塞、心力衰竭的发生率,并严重影响生活质量,是日常临床工作的重点之一[2]。一些研究从分子病理的角度对房颤发病机制进行阐释,成为更好地理解房颤和开发房颤治疗新手段的基石[3-4]。其中,miRNA作为一类广泛存在于机体各组织系统的调节物质,成为近年来研究的热点,本文将就
Atrial fibrillation is one of the most common arrhythmic diseases, and as the population ages, the prevalence and incidence have also increased year by year [1]. Atrial fibrillation can increase the incidence of stroke, thromboembolism, heart failure, and seriously affect the quality of life, is one of the focus of routine clinical work [2]. Some studies explain the pathogenesis of atrial fibrillation from a molecular pathology perspective and become the cornerstone of a better understanding of atrial fibrillation and the development of new avenues of atrial fibrillation [3-4]. Among them, miRNA has been a hot research topic in recent years, as a kind of regulator that widely exists in various tissues and organs of the body.